Real-life comparison of the afatinib and first-generation tyrosine kinase inhibitors in nonsmall cell lung cancer harboring EGFR exon 19 deletion: a Turk Oncology Group (TOG) study.
第一作者:
Burak,Bilgin
第一单位:
Medical Oncology, Ataturk Chest Disease and Chest Surgery Training and Reseasch Hospital, Ankara, Turkey. drbbilgin@hotmail.com.
作者:
医学主题词
成年人(Adult);老年人(Aged);老年人, 80以上(Aged, 80 and over);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);癌, 非小细胞肺(Carcinoma, Non-Small-Cell Lung);外显子(Exons);女(雌)性(Female);随访研究(Follow-Up Studies);基因缺失(Gene Deletion);人类(Humans);肺肿瘤(Lung Neoplasms);男(雄)性(Male);中年人(Middle Aged);肿瘤转移(Neoplasm Metastasis);预后(Prognosis);蛋白激酶抑制剂(Protein Kinase Inhibitors);回顾性研究(Retrospective Studies);存活率(Survival Rate)
DOI
10.1007/s00432-020-03501-6
PMID
33433657
发布时间
2025-07-19
- 浏览0
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文


换一批



